Trade ARVN anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Arvinas, Inc. (ARVN) is trading at US$9.39, up 0.86% today as of Sep 4, 16:00 EDT. The company has a market capitalisation of US$612.34M. Over the past 52 weeks, ARVN has traded between US$6.97 and US$14.51. On Syfe you can trade ARVN with $0 commission and add it to your watchlist.
| Previous close | US$9.31 |
|---|---|
| Market cap | US$612.34M |
| 52-week range | US$6.97 – US$14.51 |
| Volume | 449.29K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Arvinas, Inc.
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.
Year: 2018
Wedbush Adjusts Price Target on Arvinas to $12 From $11, Maintains Neutral Rating
Aug 4, 3:41 PM · MT Newswires
Rigel Pharmaceuticals Closes Licensing Deal for Breast Cancer Drug Veppanu
Jun 16, 8:31 PM · MT Newswires
BofA Securities Raises Price Target on Arvinas to $16 From $14
May 14, 11:41 AM · MT Newswires
Arvinas, Inc. (ARVN) stock is trading at US$9.39, +0.86% from the previous close of US$9.31.
The market cap for Arvinas, Inc. (ARVN) stock is approximately US$612.34M.
The 52-week high for Arvinas, Inc. (ARVN) stock is US$14.51.
The 52-week low for Arvinas, Inc. (ARVN) stock is US$6.97.
Arvinas, Inc. (ARVN) does not currently pay a dividend.
Stay on top of ARVN
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
